Long-Term Response after Early Discontinuation Due to Immunotherapy Toxicity In Metastatic Renal Cancer: A Clinical Case and Literature Review
1. Abstract Immunotherapy has a cardinal role in renal cancer, both in adju- vant setting and metastatic disease (first or subsequent lines). Se- vere immune-related adverse events (irAEs) occur in 10-27% of patients treated with immunotherapy [1,2], but the discontinuation of the treatment due to toxicity doesn’t necessarily correlate with poor outcome.